LifeSci Partners Podcast
Activity Overview
Episode publication activity over the past year
Episodes
Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry
03 Oct 2023
Contributed by Lukas
Tune into Episode #2 of the LifeSci Search podcast with Andy Cronin (President & Co-Founder) and Ayesha Price (Sr. Director, Executive Search) as ...
LifeSci Search Podcast: Episode #1
17 Mar 2023
Contributed by Lukas
Tune into Episode #1 of the LifeSci Search Podcast.
Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair
10 Feb 2023
Contributed by Lukas
In the clinical setting, the time it takes to address a serious problem can make the difference between life and death. To save as much time as possib...
A Brief Chat with Erez Raphael, CEO of DarioHealth
06 Jan 2023
Contributed by Lukas
Tune into this 17-minute chat with Erez Raphael, CEO of DarioHealth (NASDAQ: DRIO).
Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs
05 Jan 2023
Contributed by Lukas
CDK and RAS-targeting drugs already exist, but in the setting of oncology, if it’s not curative, it’s not enough. As a former practicing oncologis...
A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.
04 Jan 2023
Contributed by Lukas
Tune into this 9-minute chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc. (NYSE: PLX).
A Brief Chat with Martin Welschof, CEO of BioInvent
03 Jan 2023
Contributed by Lukas
Tune into this 17-minute chat with Martin Welschof, CEO of BioInvent (STO: BINV).
A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.
29 Dec 2022
Contributed by Lukas
Tune into this 11-minute chat with Raphi Levy, CFO of Alpha Tau Medical Ltd. (NASDAQ: DRTS).
A Brief Chat with Amir London, CEO of Kamada Ltd.
28 Dec 2022
Contributed by Lukas
In this 13-minute chat, Amir London, CEO of Kamada Ltd. (NASDAQ: KMDA), discusses the growing commercial business of the company, including six FDA-ap...
A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.
27 Dec 2022
Contributed by Lukas
In this 15-minute chat, Rob Etherington, President & CEO of Clene, Inc. (NASDAQ: CLNN) discusses the potential for nanosuspensions to improve cell...
Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound
16 Dec 2022
Contributed by Lukas
Repairing damage to living tissue often requires the removal or debridement of what was destroyed. This is usually done through surgery—an invasive ...
A Promising New Immune Checkpoint from Sensei Bio: VISTA
13 Dec 2022
Contributed by Lukas
CTLA-4 was a breakthrough; PD-1—a blockbuster, then IDO got busted and biotech retreated to the bench. It got quiet for a while, but the basic scien...
Turning Amino Acids into Drugs: A Novel Platform from Axcella Health
08 Dec 2022
Contributed by Lukas
Endogenous metabolic modulators (EMMs) are composed of amino acids and, when given in combination, have the potential to treat serious disease. With t...
Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders
17 Nov 2022
Contributed by Lukas
Drug discovery is an adventure, drug delivery is an art. The chemists at Lipocine put their experience to the test — by turning drugs with problemat...
89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin
11 Nov 2022
Contributed by Lukas
As the American obesity issue grows, the NASH and SHTG treatment markets concurrently expand. At 89bio, the idea is to use nature itself to therapeuti...
De-Risked Oncology Targets with Assets from Checkpoint Therapeutics
04 Nov 2022
Contributed by Lukas
James Oliviero, CEO of Checkpoint Therapeutics, is certain that fortunes can be won by building better and cheaper mousetraps. That’s why he is posi...
Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction
20 Oct 2022
Contributed by Lukas
The CEO of BrainsWay Ltd, Christopher von Jako, is committed to non-invasive medical technologies – particularly when it comes to the brain. A busin...
An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals
29 Sep 2022
Contributed by Lukas
It’s the circle of life: the cell cycle is a molecular merry-go-round for the propagation of all cells, including tumor cells. This process is regul...
Oncology on the Move—Artios: Financing Considerations for an Early Biotech
19 Sep 2022
Contributed by Lukas
Artios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of th...
Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience
15 Sep 2022
Contributed by Lukas
Most oncology drugs turn things off—Alligator Bioscience prefers to turn things on, specifically, the immune system, by way of stimulation with CD40...
Esperion Therapeutics: A Small Company with a Big Heart
31 Aug 2022
Contributed by Lukas
Lowering your LDL levels—so-called “bad cholesterol”—can save your life: an irrefutable observation made possible by the advent of statins. Th...
Patient-centric, Physician-managed healthcare centers that Payers love: P3 Health Partners
22 Aug 2022
Contributed by Lukas
My mother, a woman who thrived on organization, always had her entire medical history in hand when she saw a new healthcare provider—both in hard co...
Two Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu Therapeutics
04 Aug 2022
Contributed by Lukas
Ryvu’s lead asset, discovered-inhouse is RVU120, a CDK8/19 inhibitor with activity in both hematologic and solid tumor cancers currently undergoing ...
Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10
29 Jul 2022
Contributed by Lukas
Using cytokines therapeutically is like firing a shotgun at range – for sure you will hit your target, but off-target effects are likely, if not cer...
A Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) Platform
26 Jul 2022
Contributed by Lukas
An inch wide and a mile deep—that’s the sort of expertise CSO of Artios Pharma, Dr. Graeme Smith, brings his benchtop. Since his time at Cambridge...
Teclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumors
15 Jul 2022
Contributed by Lukas
Hypoxia is the key. TEC-001 is a prodrug selectively activated in hypoxic environments, such as that induced by the long-known technique called trans-...
iBreathe it in: Inhalable drug delivery with the iSPERSE platform, from Pulmatrix
11 Jul 2022
Contributed by Lukas
A car is a very efficient delivery system until you can’t find a place to park, or the spot you find is nowhere near where you wanted to go. For med...
P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)
11 Jul 2022
Contributed by Lukas
MDM2 is a key regulator of p53, the protein responsible for tumor suppression and apoptosis — an intractable, yet undruggable target. Previous attem...
An anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon Pharma
01 Jul 2022
Contributed by Lukas
The only people that like infusion suites are those who own them. Payers don’t like them. Patients hate them. But for many drugs, due to their molec...
Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO
27 Jun 2022
Contributed by Lukas
By way of an exquisite toggling of activity, HADUVIO stimulates one opioid receptor (kappa) and blocks the activity of another (mu) while avoiding the...
Special Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano Medicine
23 Jun 2022
Contributed by Lukas
If the pandemic taught us nothings else, we’ve learned the critical importance of having a dependable system for delivery. OncoNano offers two such ...
Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt
22 Jun 2022
Contributed by Lukas
Along with the first-ever approval by the FDA of a so-called checkpoint inhibitor, the anti-CTLA-4 drug Yervoy, in 2001, came vindication; the treatme...
Inducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta Biosciences
17 Jun 2022
Contributed by Lukas
There’s no point in receiving a gift you can’t keep, be it a pony, or a therapeutic. For the latter to be effective it must be retained, yet the i...
Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences
10 Jun 2022
Contributed by Lukas
There’s nothing new about transdermal delivery of drugs—patches, gadgets, and solvents abound—but each has physical limitations, and the drugs t...
Location, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with Amphiphile
13 May 2022
Contributed by Lukas
In pharmacology, getting your drug to where it’s needed is everything. In immunology, to elicit an immune response that location is often the lymph ...
Making sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point Pharma
06 May 2022
Contributed by Lukas
Innovation can sometimes be counterintuitive, as in the case with Tyrvaya, a drug approved in 2021 for the signs and symptoms of dry eye disease that ...
The sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from Athenex
22 Apr 2022
Contributed by Lukas
The allure of allogeneic “off-the-shelf” adaptive cell therapy (ACT) is obvious – by definition, the treatment is immediately available, and due...
A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System
14 Apr 2022
Contributed by Lukas
Having focused on endocrine disorders since grad school, first at the bench and later in the board room, Dr. Thierry Abribat founded and became the CE...
A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.
25 Mar 2022
Contributed by Lukas
Everyone is excited about KRAS, the “undruggable” target that now has a drug. However, that drug only hits one specific, rather rare KRAS mutation...
Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene
18 Mar 2022
Contributed by Lukas
Hear how Jay Mei, MD, PhD, went from his benchtop years at the NIH to a blockbuster launch at Celgene (think, Revlimid, after stints at Novartis and J...
Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.
10 Mar 2022
Contributed by Lukas
Proteins designed as drugs – the so-called biologics – sparked a medical revolution, but it has come at an extraordinary cost: less than 2% of Ame...
Differentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.
03 Mar 2022
Contributed by Lukas
Having the ability to activate a precise, robust and persistent immune response to kill cancer cells is what IMV is all about. Using its DPX...
Developing Drugs for Rare Diseases: Pointers and Pitfalls
28 Feb 2022
Contributed by Lukas
There are approximately 30 million individuals in the U.S. currently living with one of at least 7,000 rare diseases. The National Organization for Ra...
Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development
24 Feb 2022
Contributed by Lukas
A scar is proof you survived – a good thing. Uncontrolled scarring, called fibrosis, is a threat unto itself (think cirrhosis) or an impediment to c...
Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy
18 Feb 2022
Contributed by Lukas
In oncology, the field of neoantigen prediction is rife with proprietary mathematics for homing in on the best antigens for T cell activation. Only on...
Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER
11 Feb 2022
Contributed by Lukas
Every cancer neoantigen prediction platform has lots and lots of math – the PIONEER platform, from the Danish company, Evaxion, has data. In a phase...
Water, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana Medical
21 Jan 2022
Contributed by Lukas
Not enough fluids? Drink more. Too much fluid – entirely different, far more complex problem. From the systemic swelling caused by congestive heart ...
Modulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s Aptinyx
14 Jan 2022
Contributed by Lukas
Turning a biological process on or off is like flipping a light switch. However, these approaches often come with serious side effects that can limit ...
Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets
06 Jan 2022
Contributed by Lukas
Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the...
Captor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor Therapeutics
17 Dec 2021
Contributed by Lukas
Hear how Captor Therapeutics became a Swiss/Polish public biotech company run by a Scotsman –as told by 30-year healthcare industry veteran and Capt...
Discovery Platform for Small Molecule mRNA Drugs like no other: mRNA Lightning, from Anima Biotech
10 Dec 2021
Contributed by Lukas
For the computer expert/CEO of Anima, Yochi Slonim, it’s all the same – lots of instructions and lots of code. It could be code for AI, it could b...
Seeing clearly where the sun don’t shine: A game-changing technology in GI endoscopy from Motus GI
03 Dec 2021
Contributed by Lukas
Your GI team can’t help you if they can’t see what’s wrong. An endoscope might encounter clotted blood in the esophagus from chronic bleeds, or ...
GBS Inc: A Saliva Test for Diabetes Monitoring: An inside look at the Glucose Biosensor Technology
15 Nov 2021
Contributed by Lukas
Three facts: 1) World Diabetes Day is November 14th, which marks the 100th anniversary of the discovery and isolation of insulin. 2) There are an esti...
Lean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.
12 Nov 2021
Contributed by Lukas
He’s got patents, patience, and a plan – and a five-year runway to execute. Listen in as Dr. Amit Kumar, CEO of Anixa Biosciences, tells a tale of...
NOXXON: Targeting the Chemokines of the TME to enhance Cancer Therapies
05 Nov 2021
Contributed by Lukas
From a doctorate at the SALK Institute overlooking La Jolla Cove, to an MBA from INSEAD, the world-leading business school located near Paris, NOXXON ...
Femasys Inc: Putting the Focus on Women’s Reproductive Health
28 Oct 2021
Contributed by Lukas
After spending the first half of her career developing medical devices for others, Kathy Lee-Sepsick, founder, and CEO of Femasys sets out to address ...
To Find the best Antigens for Cancer, or COVID, Gritstone bio has the EDGE™
22 Oct 2021
Contributed by Lukas
From a famous pub in Oxford to a lab on California’s coast, Gritstone founder, and CEO Dr. Andrew Allen tells the story of how his dream, inspired b...
Vincerx Pharma: From Pharmacyclics to Cyclins – The Will and the Way
08 Oct 2021
Contributed by Lukas
Listen in while Vincerx CEO, Dr. Ahmed Hamdy shares his experience with life-changing events, a date with the cancer target CDK9, and the utterance of...
Repairing Organ Damage – Angion Biomedica
29 Sep 2021
Contributed by Lukas
Combining his medical expertise with his business acumen, Angion’s CEO, Dr. Jay Venkatesan, is focused on meaningfully improving both health outcome...
Experience, Passion, and a Plan: Vera Therapeutics, Dr. Marshall Fordyce takes us from the bedside to the boardroom in his mission to treat autoimmune disease
24 Sep 2021
Contributed by Lukas
Dr. Marshall Fordyce, CEO of Vera Therapeutics still treats patients – it is a calling he will always hear. It took him to the bedside at HIV clinic...
A Promising Repurpose: Tenax Therapeutics Tests the Cancer Drug Imatinib in Pulmonary Arterial Hypertension
17 Sep 2021
Contributed by Lukas
Christopher Giordano, MS, explains how an American English major studying at Oxford University lucked into marrying a Welsh girl he convinced to move ...
Medicenna Therapeutics: Reining in the Fire: Taming IL-2?
09 Sep 2021
Contributed by Lukas
You can fight fire with fire – it’s a thing. The problem is having anything left to salvage after the fire is out, and thus the conundrum of IL-2:...
Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage
27 Aug 2021
Contributed by Lukas
The field of cancer immunotherapy exploded in 2011 with the FDA approval of an utterly novel, so-called “checkpoint” drug, the anti-CTLA-4 agent, ...
Compugen Pioneering DNAM axis in cancer: TIGIT and PVRIG – Synergistic Checkpoints
20 Aug 2021
Contributed by Lukas
To the oncologist, human physiology is a riot of redundancies, and treating cancer is a game of whack-a-mole – target one mechanism, another pops up...
HERVs and Nerves: Targeting the viral origins of neurodegenerative disease
13 Aug 2021
Contributed by Lukas
GeNeuro's CEO, Jesus Martin-Garcia, a consummate technology entrepreneur, tells his business journey from the birth of telecoms, to the advent of onli...
Are iNKT cells the next frontier in cancer treatment?
06 Aug 2021
Contributed by Lukas
Can T cells be leveraged as a cancer therapeutic? Check. How about natural killer (NK) cells? Check. Now meet invariant natural killer (iNKT) cells –...
Pixium Vision SA: An Eye Towards the Future: High Tech Treatment for Dry AMD
29 Jul 2021
Contributed by Lukas
There are no approved treatments to treat dry macular degeneration – a disease of the eye that can lead to eventual blindness. The standard of care ...
Arcellx: Plug and Play CAR-T: Modular Immunotherapy
23 Jul 2021
Contributed by Lukas
From a training at the bedside to a benchtop at the NIH, to the realities of life on the Dark Side, Arcellex CMO, Dr. Chris Heery speaks of his passio...
A Time for Cocktails. Polytope: A Potential Treatment for Covid-19
12 Jul 2021
Contributed by Lukas
Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship ...
Getting the Bugs out of Alzheimer’s: A New Therapeutic Approach
30 Jun 2021
Contributed by Lukas
Cortexyme CEO, Casey Lynch, discusses her life-long passion for finding treatments for neurodegenerative diseases in general, and Alzheimer’s in par...
Switching it Up: Medigene Charts a New Course
28 Jun 2021
Contributed by Lukas
Medigene CEO, Dolores Schendel, takes us from her Midwestern roots to the helm of Bavaria’s Medigene AG. Along the way, she explains how her trainin...
Cancer Treatment Goes Viral Featuring: Dr. Matt Coffey, CEO Oncolytics Biotech
18 Jun 2021
Contributed by Lukas
Dr. Coffey explains how a phenomenon first observed over a 100 years ago – that a systemic infection can cure cancer – became the blanket term for...
BiomX: A Real Phage-Turner
04 Jun 2021
Contributed by Lukas
BiomX co-founder, Jonathan Solomon, gained his early scientific training in physics, and electrical engineering during a ten-year stint in an Israeli ...
NK cell biology no longer stands for “Not Known”: Michael A. Caligiuri, M.D., Chief Medical Officer, and Co-founder of CytoImmune Therapeutics
12 May 2021
Contributed by Lukas
Dr. Caligiuri describes his journey from being a liberal arts major at a college in upstate New York, to being a Stanford trained MD, to his current p...